Fatigue in patients with systemic lupus erythematosus: The role of dehydroepiandrosterone sulphate

Lupus

Volumn 21, Issue 14, 2012, Pages 1515-1521

  Overman, C L ^a   Hartkamp, A ^b,c   Bossema, E R ^a   Bijl, M ^d   Godaert, G L R ^a   Bijlsma, J W J ^b   Derksen, R H W M ^b   Geenen, R ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

dehydroepiandrosterone; fatigue; prednisone; Systemic lupus erythematosus

Indexed keywords

ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRASTERONE; PRASTERONE SULFATE; PREDNISONE;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RATING SCALE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; FATIGUE; FEMALE; GLUCOCORTICOIDS; HUMANS; LUMINESCENT MEASUREMENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREDNISONE; PSYCHOMETRICS; YOUNG ADULT;

EID: 84869477404     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312459105     Document Type: Article

References (43)

1. Crosbie D, Black C, McIntyre L, Royle PL, Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev 2007; CD005114.
2. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007 ; 369: 587-596
3. Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus?. Lupus. 2012 ; 21: 465-476
4. Bruce IN, Mak VC, Hallett DC, Gladman DD, Urowitz MB. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999 ; 58: 379-381
5. Burgos PI, Alarcón GS, McGwin G, Crews KQ, Reveille JD, Vilá LM. Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum. 2009 ; 61: 1179-1186
6. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol. 2002 ; 29: 482-486
7. Sweet JJ, Doninger NA, Zee PC, Wagner LI. Factors influencing cognitive function, sleep, and quality of life in individuals with systemic lupus erythematosus: a review of the literature. Clin Neuropsychol. 2004 ; 18: 132-147
8. Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford). 2000 ; 39: 1249-1254
9. Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol. 1998 ; 25: 892-895
10. Tayer WG, Nicassio PM, Weisman MH, Schuman C, Daly J. Disease status predicts fatigue in systemic lupus erythematosus. J Rheumatol. 2001 ; 28: 1999-2007
11. Da Costa D, Dritsa M, Bernatsky S, et al. Dimensions of fatigue in systemic lupus erythematosus: relationship to disease status and behavioral and psychosocial factors. J Rheumatol. 2006 ; 33: 1282-1288
12. Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol. 2005 ; 32: 1699-1705
13. Derksen RHWM. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. Semin Arthritis Rheum. 1998 ; 27: 335-347
14. Hedman M, Nilsson E, De la Torre B. Low sulpho-conjugated steroid hormone levels in systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 1989 ; 7: 583-588
15. Lahita RG, Bradlow HL, Ginzler E. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. 1987 ; 30: 241-248
16. Arlt W. Dehydroepiandrosterone replacement therapy. Curr Opin Endocrinol Diabetes. 2006 ; 13: 291-305
17. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000 ; 85: 4650-4656
18. Chang DM, Lanv JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 ; 46: 2924-2927
19. Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Rönnblom L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005 ; 38: 531-540
20. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 1995 ; 38: 1826-1831
21. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004 ; 50: 2858-2868
22. Hartkamp A, Geenen R, Godaert GLR, Bijl M, Bijlsma JWJ, Derksen RHWM. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis. 2010 ; 69: 1144-1147
23. Thumboo J, Fong KY, Chan SP, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000 ; 27: 1414-1420
24. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
25. Hartkamp A, Geenen R, Godaert GLR, et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. Ann Rheum Dis. 2008 ; 67: 91-97
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992 ; 35: 630-640
27. Smets EMA, Garssen B, Bonke B, De Haes JCJM. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 ; 39: 315-325
28. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol. 2000 ; 27: 377-379
29. Abrahamowicz M, Fortin PR, Du BR, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol. 1998 ; 25: 277-284
30. Cutolo M, Capellino S, Sulli A, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006 ; 1089: 538-547
31. Kuratsune H, Yamaguti K, Sawada M, et al. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med. 1998 ; 1: 143-146
32. Scott LV, Salahuddin F, Cooney J, Svec F, Dinan TG. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. J Affective Disord. 1999 ; 54: 129-137
33. Van Rensburg SJ, Potocnik FCV, Kiss T, et al. Serum concentrations of some metals and steroids in patients with chronic fatigue syndrome with reference to neurological and cognitive abnormalities. Brain Res Bull. 2001 ; 55: 319-325
34. Cleare AJ, O'Keane V, Miell JP. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. Psychoneuroendocrinology. 2004 ; 29: 724-732
35. Turan T, Izgi HB, Ozsoy S, et al. The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome. Psychiatr Invest. 2009 ; 6: 204-210
36. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab. 1998 ; 83: 3130-3133
37. Takebayashi M, Kagaya A, Uchitomi Y, et al. Plasma dehydroepiandrosterone sulfate in unipolar major depression. J Neural Transm. 1998 ; 105: 537-542
38. Sonnenschein M, Mommersteeg PMC, Houtveen JH, Sorbi MJ, Schaufeli WB, van Doornen LJP. Exhaustion and endocrine functioning in clinical burnout: an in-depth study using the experience sampling method. Biol Psychol. 2007 ; 75: 176-184
39. Köller MD, Templ E, Riedl M, et al. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis. 2004 ; 63: 1677-1680
40. Gutiérrez MA, Garcia ME, Rodriguez JA, Rivero S, Jacobelli S. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus. 1998 ; 7: 404-408
41. Van der Goes MC, Bossema ER, Hartkamp A, et al. Cortisol during the day in patients with systemic lupus erythematosus or primary Sjögren's syndrome. J Rheumatol. 2011 ; 38: 285-288
42. Kancheva R, Hill M, Novak Z, Chrastina J, Kancheva L, Starka L. Neuroactive steroids in periphery and cerebrospinal fluid. Neuroscience. 2011 ; 191: 22-27
43. Straub RH, Lehle K, Herfarth H, et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur J Endocrinol. 2002 ; 146: 365-374